Ra capital management director buys $412,776 in Artiva Biotherapeutics By Investing.com

RA Capital Management, L.P., a reporting person identified as both a director and a 10% owner of Artiva Biotherapeutics, Inc. (), acquired 41,319 shares of the company’s common stock on July 24, 2026. The total value of these shares purchased amounted to $412,776.

The shares were acquired at a weighted average price of $9.99 per share, with individual transaction prices ranging from $9.96 to $10.00. The purchase comes as ARTV stock trades at $10.53, showing remarkable momentum with a 262% return over the past year and 154% gain in the last six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, though analysts maintain price targets ranging from $23 to $41. InvestingPro offers 11 additional exclusive tips for ARTV investors.

Following this transaction, RA Capital Management, L.P. indirectly holds a significant stake in Artiva Biotherapeutics. The shares are held across several entities: 17,283,802 shares by RA Capital Healthcare Fund, L.P., 264,571 shares by RA Capital Nexus Fund, L.P., 826,832 shares by RA Capital Nexus III Fund, L.P., and 68,320 shares through a separately managed account. RA Capital Management, L.P. serves as the investment manager for these funds and the account, and along with its general partner and managing members, disclaims beneficial ownership except to the extent of their pecuniary interest. Laura Stoppel, a partner of the Adviser, serves on Artiva Biotherapeutics’ board of directors.

In other recent news, Artiva Biotherapeutics has received significant attention following the FDA’s Regenerative Medicine Advanced Therapy designation for its rheumatoid arthritis treatment, AlloNK, in combination with rituximab. This designation is expected to expedite the development and review process of the therapy. Additionally, Artiva presented promising clinical data at the European Alliance of Associations for Rheumatology Congress, revealing that 71% of patients in a Phase 2a trial achieved a notable ACR50 response after six months of follow-up. Cantor Fitzgerald has reiterated an Overweight rating for Artiva Biotherapeutics, maintaining a $40.00 price target, reflecting confidence in the company’s strategy and clinical data. Furthermore, Artiva announced executive changes, with Diego Miralles, M.D. stepping down from the board to assume the role of President and Head of Research and Development. His resignation from the board reduced its size from eight to seven members. These developments highlight Artiva’s ongoing efforts in advancing its therapeutic offerings and refining its leadership structure.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.